Ontology highlight
ABSTRACT: Background
This multicenter phase 1b/2 trial aimed to explore the maximum tolerated dose (MTD), activity, and safety of anlotinib plus chemotherapy in patients with T790M-negative epidermal growth factor receptor (EGFR)-mutant advanced nonsquamous non-small cell lung cancer (NSCLC) after resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs).Methods
In the phase 1b stage, patients received anlotinib (8/10/12 mg, days 1-14) combined with cisplatin (75 mg/m2 , day 1) or carboplatin (AUC = 5, day 1) plus pemetrexed (500 mg/m2 , day 1) for a 3-week cycle based on a 3 + 3 dose-escalation design. In the phase 2 single-arm stage, anlotinib was administered at MTD combined with platinum plus pemetrexed for four cycles, followed by anl
SUBMITTER: Li J
PROVIDER: S-EPMC9750808 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature